A nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain, and its preparation method and application

By coupling TAT polypeptide and lactoferrin on chitosan nanoparticles, a nanodrug delivery system that is actively targeted through the nasal brain has been designed, which solves the problem of DAPTA delivery to the brain and achieves efficient nasal administration and intake Brain delivery significantly improves the therapeutic effect.

CN118021764BActive Publication Date: 2024-11-26CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410218434.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-28
Publication Date
2024-11-26
Estimated Expiration
2044-02-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver the CCR5 peptide antagonist DAPTA to the brain through the nasal pathway, which is limited by the blood-brain barrier, resulting in poor treatment effect. Nasal administration faces problems such as biodegradation, mucosal cilia clearance and poor penetration.

Method used

Using drug-laden chitosan nanoparticles and coupling TAT polypeptide and lactoferrin on their surface, designing a cognitive function of active targeted therapy through nasal brain by improving the bioadhesion and penetration ability of nanoparticles. Obstacle nanodrug delivery system.

Benefits of technology

It significantly improves the non-invasive intranasal targeted delivery efficiency and brain entry volume of DAPTA, enhances the active targeting ability of nasal and brain, and improves the treatment effect of cognitive dysfunction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118021764B_ABST
    Figure CN118021764B_ABST
Patent Text Reader

Abstract

The present invention discloses a nano drug delivery system for actively targeting the brain to treat cognitive dysfunction, and its preparation method and application, belonging to the field of medicine. The nano drug delivery system includes chitosan nanoparticles encapsulating drugs, and TAT polypeptides and brain targeting peptides / nerve targeting peptides coupled to the surface of the chitosan nanoparticles. The nano drug delivery system prepared by the present invention actively targets the nose, and significantly increases the amount of DAPTA entering the brain by increasing the uptake of the trigeminal nerve and the olfactory nerve, which has important clinical value and significance for treating cognitive dysfunction by DAPTA.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to a nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain, and a preparation method and application thereof. Background Art

[0002] Cognitive dysfunction diseases are a class of neurological diseases involving cognitive function, including Alzheimer's disease, Parkinson's disease, cerebrovascular disease, traumatic brain injury, etc. These diseases are particularly common in the elderly population, bringing huge life burdens to patients and their families. In clinical practice, non-specific treatments such as anti-inflammatory, neuroprotective agents, and neuroregeneration promoters are often used to treat cognitive dysfunction diseases. However, there is no effective strategy to directly promote the recovery of neurocognitive function. CCR5 is a new therapeutic target. CCR5 peptide antagonist-DAPTA can improve cognitive function after entering the brain, but CCR5 is widely distributed in the periphery and there are blood-brain barrier restrictions, which makes the peripheral administration of DAPTA poorly controllable and the therapeutic effect is poor. Therefore, there is an urgent need to develop strategies to effectively deliver DAPTA to the brain to treat cognitive dysfunction.

[0003] Intranasal (In) delivery of therapeutic drugs to the brain has emerged as a promising noninvasive technology that can bypass the blood-brain barrier. The nasal-to-brain pathway allows drugs to enter the brain directly via the olfactory or trigeminal pathways. In administration has several advantages, such as avoiding drug degradation in the gastrointestinal tract and first-pass effects in the liver. In addition, drug delivery can provide rapid pharmacokinetics, minimize peripheral tissue exposure, reduce dosing requirements, fewer adverse side effects, and good patient compliance. Despite these promising properties, In drug delivery still faces certain challenges, including local enzymatic degradation of biotherapeutics, rapid mucociliary clearance of drugs, and poor mucosal penetration. Nanocarrier-based delivery systems have recently addressed some of the above limitations by protecting drugs from degradation and circumventing p-glycoprotein efflux. Properties such as enhanced bioadhesion and mucus penetration remain essential for In delivery nanocarriers to achieve enhanced brain delivery. However, there is currently a lack of new nasal drug delivery nanosystems with optimal particle size, prolonged bioadhesion at the absorption site, ability to penetrate mucus, and improved intracellular / extracellular transport along neural pathways. Therefore, the preparation of new nasal drug delivery nanosystems with the above characteristics is of great significance to ensure the success of DAPTA-based TBI treatment. Summary of the invention

[0004] The purpose of the present invention is to provide a nano drug delivery system for active intranasal targeted treatment of cognitive dysfunction and its preparation method and application, so as to solve the problems existing in the above-mentioned prior art. The present invention can significantly improve the non-invasive intranasal targeted delivery of DAPTA, which has important clinical value and significance for the treatment of cognitive dysfunction.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The present invention provides a nano drug delivery system for actively targeting the brain to treat cognitive dysfunction via the nose. The nano drug delivery system comprises chitosan nanoparticles encapsulating drugs, and TAT polypeptide and lactoferrin coupled to the surface of the chitosan nanoparticles.

[0007] Preferably, the drug comprises a CCR5 peptide antagonist, and the amino acid sequence of the TAT polypeptide (SEQ ID NO: 1) is CYGRKKRRQRRR.

[0008] The present invention also provides a method for preparing the nano drug delivery system for active transnasal brain targeted treatment of cognitive dysfunction, comprising the following steps:

[0009] The drug and chitosan are mixed to obtain drug-encapsulated chitosan, and the drug-encapsulated chitosan is then mixed with sodium tripolyphosphate for reaction, followed by centrifugation, and nanoparticles are collected and freeze-dried to obtain drug-encapsulated chitosan nanoparticles;

[0010] The drug-loaded chitosan nanoparticles are mixed with succinimide 3-(2-pyridyldisulfide)-propionate for reaction, followed by dialyzing to obtain a mixed solution; the mixed solution is mixed with TAT polypeptide and lactoferrin, stirred for reaction, and then dialyzed to obtain a nano drug delivery system for active nose-brain targeted treatment of cognitive dysfunction.

[0011] Preferably, the drug-loaded chitosan is prepared by loading 50-250 μg of drug per 4-5 mg of chitosan, and the mass volume ratio of chitosan to sodium triphosphate is 1:1-5:1;

[0012] The drug-loaded chitosan is mixed with the sodium triphosphate, stirred at room temperature for reaction for 30-60 minutes, and centrifuged at 10000-15000 rpm for 20-30 minutes.

[0013] Preferably, the mass ratio of the drug-loaded chitosan nanoparticles to the succinimide 3-(2-pyridyldisulfide)-propionate is 1:0.1;

[0014] The drug-loaded chitosan nanoparticles are mixed with succinimide 3-(2-pyridyldisulfide)-propionate, stirred at room temperature for reaction for 5-10 hours, and dialyzed with ultrapure water for 5-10 hours.

[0015] Preferably, the molar ratio of the succinimidyl 3-(2-pyridyldisulfide)-propionate, the TAT polypeptide and lactoferrin is 2:1:1;

[0016] The mixed solution is mixed with TAT polypeptide and lactoferrin, stirred at room temperature for 30-60 minutes, and dialyzed with ultrapure water for 5-10 hours.

[0017] The present invention also provides application of the nano drug delivery system in preparing a drug for improving the efficiency of non-invasive intranasal targeted delivery of DAPTA.

[0018] The present invention also provides application of the nano drug delivery system in preparing drugs for improving the amount of DAPTA entering the brain.

[0019] The present invention also provides application of the nano drug delivery system in preparing drugs for treating cognitive dysfunction.

[0020] The present invention discloses the following technical effects:

[0021] The present invention utilizes TAT ​​polypeptide and lactoferrin to modify chitosan nanoparticles encapsulating DAPTA to prepare a nano drug delivery system. Experimental verification shows that the nano drug delivery system can significantly promote the ability to penetrate the mucosal epithelial barrier and has a significant efficiency of being phagocytosed by nerve cells. At the same time, it is proved that the nano drug delivery system increases the amount of drug entering the brain by increasing the uptake of the trigeminal nerve and the olfactory nerve, indicating that the nano drug delivery system prepared by the present invention can achieve active targeting of the nose and brain, and can deliver DAPTA through non-invasive intranasal targeted delivery, thereby improving the effect of DAPTA in treating cognitive dysfunction, which is of great significance for the clinical treatment of cognitive dysfunction. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0023] Figure 1 The transmission electron microscopy image (A), hydrated particle size (B) and zeta potential (C) of DA@LT NPs of the present invention;

[0024] Figure 2 Schematic diagram of grafting Lf and TAT onto DA NPs by conjugation method; the red negatively charged lines in the figure represent TPP, the blue positively charged lines represent chitosan, and the green lines represent DAPTA;

[0025] Figure 3 The results of infrared spectroscopy characterization of DA@LT NPs;

[0026] Figure 4To detect the release of DAPTA from DA@LT NPs under different pH conditions;

[0027] Figure 5 Schematic diagram of DA@LT NPs crossing the nasal mucosal barrier;

[0028] Figure 6 To detect the statistical results of the efficiency of DA@LT NPs passing through the nasal mucosa;

[0029] Figure 7 Confocal images of the phagocytosis efficiency of DA@LT NPs by neurons;

[0030] Figure 8 In vivo imaging of small animals to detect the amount of DA@LT NPs entering the brain;

[0031] Fig. 9 IVIS imaging to confirm that DA@LT NPs increase the uptake into the trigeminal nerve and olfactory bulb, thereby increasing the amount entering the brain. DETAILED DESCRIPTION

[0032] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0033] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0034] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0035] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0036] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0037] DAPTA: CCR5 inhibitor;

[0038] TPP: sodium tripolyphosphate;

[0039] Lf: lactoferrin;

[0040] TAT: cell-penetrating peptide, amino acid sequence CYGRKKRRQRRR, synthesized by Xi'an Ruixi Biotechnology Co., Ltd.;

[0041] SH-Lf protein: thiolated lactoferrin;

[0042] SPDP: succinimidyl 3-(2-pyridyldithio)-propionate;

[0043] Example 1 A method for preparing a nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose-brain pathway

[0044] 1. Preparation of DAPTA-loaded chitosan nanomedicine

[0045] 2.7 mL of chitosan solution (1.7 mg mL -1 ) was mixed with different amounts of DAPTA (50, 100, 150, 200, 250 μg) to form chitosan loaded with DAPTA, and then sodium tripolyphosphate (TPP, 5 mg mL -1 ), wherein chitosan and TPP were mixed in different ratios of 1:1, 3:1, and 5:1 (wt / wt), and stirred for 30 min. Nanoparticles were collected by centrifugation at 12000 rpm for 30 min, and freeze-dried to obtain DAPTA-loaded chitosan nanoparticles (DA NPs).

[0046] Determination of DAPTA encapsulation efficiency: DAPTA was labeled with Cy5 and the Cy5 ultraviolet absorption of DA NPs was measured. The results showed that the optimal DAPTA dosage was 200 μg.

[0047] The measurement of DA NPs particle size showed that the optimal mass-to-volume ratio of chitosan:TPP was 3:1 and the particle size of DA NPs was 100-120nm.

[0048] 2. Preparation of DA NPs modified with lactoferrin (Lf) and cell-penetrating peptides

[0049] SPDP was added to DA NPs with a mass ratio of DA NPs to SPDP of 1:0.1. The mixture was stirred at room temperature for 6 h, and dialyzed rapidly with ultrapure water for 6 h to remove unreacted SPDP to obtain S-DA NPs. TAT polypeptide and SH-Lf protein (the molar ratio of SPDP, TAT polypeptide and SH-Lf protein was 2:1:1) were then added to the S-DA NPs solution, the mixture was stirred at room temperature for 30 min, and dialyzed rapidly with ultrapure water for 6 h to remove unreacted TAT and lactoferrin to obtain DA@LT NPs. The mixture was freeze-dried, sealed and placed at -20°C for later use.

[0050] Example 2 Structural Characterization of DA@LT NPs

[0051] After negative staining with 0.3% uranyl acetate solution, the morphology of DA@LT NPs was observed using a transmission electron microscope (TEM, EM200CX; JEOL Co., Ltd.) in bright field mode. TEM images showed that the average particle size of DA@LT NPs was about 100 nm with a spherical morphology (see Figure 2). Figure 1 Dynamic light scattering (DLS) analysis confirmed that the average hydrodynamic diameter of DA@LT NPs was approximately 150 nm with a narrow size distribution (see Figure 1 Compared with the unmodified DA NPs, the average Zeta potential of the DA NPs modified with TAT peptide molecules and Lf increased from 42 mv ± 1.3 mv to 36.74 ± 0.38 mv (see Figure 1 (C) This decrease in zeta potential confirms that the positively charged TAT and Lf were successfully attached to DA NPs.

[0052] Example 3 Infrared spectroscopy (FTIR) characterization

[0053] FTIR spectroscopy was used to verify that Lf and TAT were grafted onto DANPs and DA@LT NPs were successfully prepared. The specific steps are as follows:

[0054] In order to couple TAT peptide and Lf to the surface of DANPs, DANPs were treated with succinimidyl 3-(2-pyridyldisulfide)-propionate (SPDP) to introduce pyridyldisulfide groups on the surface of DANPs. Subsequently, TAT peptide and Lf were coupled to DANPs by addition reaction. The specific conjugation method is as follows Figure 2 The coupling between Lf and TAT was characterized by Fourier transform infrared spectroscopy.

[0055] like Figure 3 As shown, the results show that at 2950cm -1 The peak at 1376 cm is attributed to the red shift of the thioether bond of SPDP. -1The peak at is attributed to CN stretching vibration. The appearance of these two peaks confirms the successful coupling of SPDP and chitosan.

[0056] Example 4 Detection of DAPTA release rate of DA@LT NPs under different pH conditions

[0057] DAPTA labeled with Cy5 was used, and the Cy5 fluorescence intensity was evaluated using a microplate reader (BD, USA). Subsequently, a standard curve was established to determine the DAPTA packaging efficiency. Next, DA@LT NPs were incubated in a dialysis bag containing 30 mL of PBS at 37 °C, DA@LT NPs labeled with Cy5 in phosphate buffered saline (PBS) at pH 7.4 or 6.8, and stirred at 110 rpm. Every 12 h, a portion of PBS was collected, its fluorescence intensity was measured, and it was supplemented with an equal amount of PBS to determine the in vitro release rate of DAPTA.

[0058] The results are as follows Figure 4 As shown, the release of DAPTA occurred faster within the initial 6 h at pH 6.8 compared with pH 7.4, indicating that DAPTA is more easily released in a weakly acidic environment.

[0059] Example 5 Detection of the ability of DA@LT NPs to cross the nasal mucosal barrier

[0060] HNEpC cells were cultured at 1×10 5 The cells were introduced into the upper chamber of a 24-well transwell with a pore size of 0.4 μm at a density of 10 cells / well. After 72 hours, the transendothelial resistance (TEER) of the cell monolayer was evaluated using an epithelial voltmeter (Millicell-ERS-2, Millipore, USA) to verify the integrity of the barrier. Cells with a resistance of more than 200Ω were selected for subsequent experiments. Subsequently, the upper solution was discarded, and various NPs labeled with rhodamine were incubated with HNEPC cells. After 12 hours of culture, the fluorescence intensity of the solution in the lower chamber was measured using a fluorescence spectrophotometer.

[0061] Schematic diagram of crossing the nasal mucosal barrier Figure 5 The efficiency of DA@LT NPs passing through the nasal mucosa is shown in Figure 6As shown, the results showed that a higher number of nanoparticles in the lower chamber was observed in Transwells treated with DANPs modified with TAT alone (DA@TAT NPs) or DA PAs modified with TAT and Lf (DA@LT NPs) compared to the group incubated with naked DANPs. DA@TATNPs and DA@LT NPs showed similar efficiency in HNEpC transport, which was approximately 2-3 times that of the naked DA NPs group. The above results indicate that TAT modification significantly promotes the ability to penetrate the mucosal epithelial barrier.

[0062] Example 6 Detection of the phagocytic efficiency of DA@LT NPs by neural cells

[0063] This example evaluates the uptake of various NPs by neuronal cells. Human neuroblastoma cells (SH-SY5Y cells) were incubated with NPs with different surface coatings at 37°C for 2 hours and then imaged using confocal laser scanning microscopy (CLSM). Figure 7 As shown, cells incubated with naked DA NPs showed minimal fluorescence signals; in contrast, DA@TATNPs or DA@LT NPs showed significantly higher fluorescence signals, indicating that more NPs were internalized by SHSY-5Y cells. It is noteworthy that among all NPs, DA@LT NPs showed the most significant cellular uptake, as evidenced by the strong fluorescence signals inside the cells.

[0064] Example 7 Animal in vivo imaging experiment

[0065] In order to preliminarily study the targeting and retention time of drugs after nasal administration, the present invention uses chitosan nanoparticles loaded with Cy5-labeled DAPTA. Intranasal administration was performed on mice with cognitive dysfunction while anesthetized with isoflurane. In vivo fluorescence imaging was performed using an in vitro / in vivo imaging system (in vivo Master, China) 2 hours and 48 hours after injection. In addition, the brains of mice were dissected, and the distribution and intensity of Cy5 fluorescence in the collected organs were measured.

[0066] like Figure 8As shown in the figure, the results showed that negligible fluorescence signals were detected in the brains of mice injected with free DAPTA, indicating that free DAPTA has limited efficiency in reaching the brain after intranasal delivery, possibly due to its poor ability to cross various biological barriers. Encapsulation of DAPTA in chitosan-based nanocarriers did result in a slight increase in brain accumulation compared with free DAPTA. This marginal improvement may be attributed to the protective effect of the nanocarriers, which protect the peptide from degradation, as well as the inherent mucoadhesive properties of chitosan. In contrast, the brain fluorescence signal was significantly increased after administration of DA@TAT NPs or DA@Lf NPs, indicating that both TAT and Lf modifications promoted nose-to-brain transport. The DA@LT NPs group showed the most robust fluorescence signal in the brain, surpassing the other groups. This strong signal was still evident even after 48 hours, confirming that DA@LT NPs significantly enhanced the transport of DAPTA into the brain after increased intranasal pinocytosis. For a more intuitive comparison, the brains of each group were collected for IVIS imaging at 2 hours or 48 hours after administration. Consistently, DA@LT NPs showed the strongest fluorescence signal, which was 5.6, 4.0, 2.3, and 1.8 times that of free DAPTA, DANPs, DA@TAT NPs, and DA@LfNPs, respectively. Ex vivo brain imaging also showed that the fluorescence signal was mainly concentrated in the olfactory bulb of mice at 2 hours, highlighting the key role of the olfactory bulb neural pathway in promoting the transport of NPs into the brain.

[0067] Further verification of DA@LT NPs by increasing the uptake of trigeminal nerve and olfactory bulb increases the amount of brain. The present invention separated the trigeminal nerve after dissecting the mouse brain and used IVIS to monitor its fluorescence intensity. The results are as follows Fig. 9 As shown, quantitative results showed that all NPs-treated mice exhibited significant fluorescent signals in the trigeminal nerve, with the DA@LT NPs group showing the most significant signal intensity. This in vivo brain accumulation experiment is consistent with the above in vitro cell experiments, highlighting that modifying DANPs with TAT peptides that penetrate the nasal epithelial cell barrier and cross Lf neurons significantly enhances their transport from the nose to the brain.

[0068] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain, characterized in that: The nano drug delivery system comprises a drug, chitosan nanoparticles for encapsulating the drug, and TAT polypeptide and lactoferrin coupled to the surface of the chitosan nanoparticles; the preparation method of the nano drug delivery system for active transnasal brain targeted treatment of cognitive dysfunction comprises the following steps: The drug and chitosan are mixed to obtain drug-encapsulated chitosan, and the drug-encapsulated chitosan is then mixed with sodium tripolyphosphate for reaction, followed by centrifugation, and nanoparticles are collected and freeze-dried to obtain drug-encapsulated chitosan nanoparticles; The chitosan nanoparticles loaded with the drug are mixed and reacted with succinimide 3-(2-pyridyldisulfide)-propionate, and then dialyzed to obtain a mixed solution; the mixed solution is mixed with TAT polypeptide and lactoferrin, stirred for reaction, and then dialyzed to obtain a nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain; The drug-loaded chitosan is prepared by loading 50-250 μg of drug per 4-5 mg of chitosan; the mass ratio of chitosan to sodium triphosphate is 3:1-5:1; The mass ratio of the drug-loaded chitosan nanoparticles to the succinimide 3-(2-pyridyldisulfide)-propionate is 1:0.1; The molar ratio of the succinimidyl 3-(2-pyridyldisulfide)-propionate, the TAT polypeptide and lactoferrin is 2:1:1; The drug is DAPTA.

2. The nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain as claimed in claim 1, characterized in that: The amino acid sequence of the TAT polypeptide is CYGRKKRRQRRR.

3. The nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain as claimed in claim 1, characterized in that: The drug-loaded chitosan is mixed with the sodium triphosphate, stirred at room temperature for reaction for 30-60 minutes, and centrifuged at 10000-15000 rpm for 20-30 minutes.

4. The nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain as claimed in claim 1, characterized in that: The drug-loaded chitosan nanoparticles are mixed with succinimide 3-(2-pyridyldisulfide)-propionate, stirred at room temperature for reaction for 5-10 hours, and dialyzed with ultrapure water for 5-10 hours.

5. The nano drug delivery system for active targeted treatment of cognitive dysfunction via the nose and brain as claimed in claim 1, characterized in that: The mixed solution is mixed with TAT polypeptide and lactoferrin, stirred at room temperature for 30-60 minutes, and dialyzed with ultrapure water for 5-10 hours.

6. Use of the nano drug delivery system as described in any one of claims 1 to 5 in the preparation of a drug for improving the efficiency of non-invasive intranasal targeted delivery of DAPTA.

7. Use of the nano drug delivery system as described in any one of claims 1 to 5 in the preparation of a drug for increasing the amount of DAPTA entering the brain.

8. Use of the nano drug delivery system according to any one of claims 1 to 5 in the preparation of drugs for treating cognitive dysfunction.

Citation Information

Patent Citations

  • Application of chitosan nanogel loaded with oxytocin in preparation of medicine for early intervention of Alzheimer's disease

    CN113694176A